CNR1 and Obesity: Attempts have been made to improve cardiometabolic health by inverse CB1R agonism using rimonabant in humans (17, 18, 19) and the early Rimonabant in Obesity-Lipids trial showed that rimonabant improved atherogenic dyslipidemia (20).